A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05654623 |
|
Recruitment Status :
Recruiting
First Posted : December 16, 2022
Last Update Posted : April 25, 2024
|
Sponsor:
Pfizer
Collaborator:
Arvinas Estrogen Receptor, Inc.
Information provided by (Responsible Party):
Pfizer
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 14, 2024 |
| Estimated Study Completion Date : | May 15, 2028 |